Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Veracyte, Inc. (VCYT) is a profitable genomic diagnostics company anchored by its Decipher prostate cancer test and Afirma thyroid test, supported by a deep base of proprietary clinical evidence. We own it...
— Chad Meade
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Veracyte Inc
Veracyte ($VCYT) is a specialized molecular diagnostics company developing advanced genomic assays that assist oncologists in accurately diagnosing complex cancers and avoiding unnecessary surgical interventions. While the manager...
Veracyte is a cancer diagnostics developer whose shares dropped following news of potentially ending funding for its loss-making French subsidiary. The manager considers...
More institutional theses from Meridian Small Cap Growth Fund
Hinge Health's stock advanced following an earnings beat, an upward revision to full-year guidance, and accelerating client bookings. The company also...
Definium's stock more than doubled following strong Phase 3 results for its LSD-based major depressive disorder therapy, which exhibited durable treatment effects and high remission rates. This clinical milestone...
Tandem Diabetes Care is an automated insulin delivery technology provider poised for long-term growth in both Type 1 and Type 2 diabetes markets. Although near-term U.S....